Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Ramsay Health Care (RHC) Report – What You Need To Know

Leading healthcare provider Ramsay Health Care Limited (ASX: RHC) released its 2019 full-year results to the market today. Here’s what you need to know.

About Ramsay Health Care

Ramsay is the largest private hospital operator in Australia, Scandinavia and France, while also having a major presence in the UK. The company has been operating for more than 50 years, after being established by Paul Ramsay AO in Sydney in 1964. Ramsay has 480 facilities across 11 countries with 77,000 staff, annually treating around 8.5 million patients.

Here Are The 5 Key Points

  • Revenue increased by 24.4% to $11.4 billion
  • EBITDA of $1.6 billion, up 14.1%
  • Core NPAT of $590.9 million, representing a 2% increase on FY18
  • Core EPS of 285.8 cents, up 2.1%
  • Fully-franked final dividend of 91.5 cents, up 5.8%

Segment Results

Ramsay’s Australian operations delivered overall EBITDA growth of 6% on the prior corresponding period (pcp), which management viewed positively given the uncertainty around the potential impact of the Federal election on the private health sector.

Continental Europe delivered a result in-line with company expectations, with revenue up 2.6%. The acquisition of Swedish healthcare company Capio was completed during the period and Ramsay is in the advanced stages of integration.

After a poor start to the financial year, Ramsay’s UK segment strengthened in the second half showing solid revenue and EBIT growth, which was helped by a return to National Health Service (NHS) volume growth. Growth in NHS volumes was 7.4% on the pcp.

Ramsay’s Asian joint venture, Ramsay Sime Darby, posted strong operating performances in both Indonesia and Malaysia, as well as a 10% overall increase in admissions. During the period, Ramsay also opened its first day surgery in Hong Kong.

Balance Sheet & Dividend

Ramsay’s net debt position worsened during the period, extending out to $4.85 billion, which was partially attributable to the debt funding used to complete the Capio acquisition.

The company declared a fully-franked final dividend of 91.5 cents, up 5.8%, bringing the full-year dividend to 151.5 cents fully-franked. This represents a 5.2% increase on the FY18 dividend and means that Ramsay shares are currently trading at a ~2.2% dividend yield.

The Rask Finance video below explains franking credits:

Analyst Estimates

Bloomberg analysts were expecting NPAT of $540.27 million and a 89.7 cent final dividend. Ramsay beat both of these estimates by ~9% and ~2% respectively.

Management Commentary

Commenting on Ramsay’s 2019 financial year, Managing Director Craig McNally said: “In FY19, a focus on growth and enhancing our operating model saw Australia and Continental Europe achieve earnings growth. We continue to be well placed in these markets with market leading positions in Australia, France and Scandinavia, which enables us to achieve improved economies of scale, best practice, cost leadership and innovation”.

McNally also went on to discuss the consolidation of Ramsay’s position as a leading international healthcare service provider, saying, “Our scale and size gives us the opportunity to explore greater efficiencies and to establish stronger partnerships, which will generate earnings growth along the healthcare value chain.”

FY20 Outlook

According to management, industry fundamentals are continuing to drive increased demand. The company provided core EPS growth guidance on a like-for-like basis of 2% to 4% for FY20.

Ramsay is also anticipating stronger admissions volume growth, which is enhanced by its brownfield investment program in Australia and the turnaround in NHS volumes in the UK.

What Now?

Rask Media writer Jaz Harrison has previously written an article outlining the positives and negatives of an investment in Ramsay Health Care. I tend to agree with Jaz’s sentiments in that whilst Ramsay is a proven performer that looks set to ride the tailwinds of ageing populations, I don’t believe its current growth prospects justifies the recent share price.

Ramsay isn’t the only lower-risk ASX share to consider. The stocks in the free report below are all proven and reliable long term businesses.

[ls_content_block id=”14945″ para=”paragraphs”]

At the time of writing, Cathryn has no financial interest in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content